Relaxin Positively Influences Ischemia-Reperfusion Injury in Solid Organ Transplantation: A Comprehensive Review.
In recent decades, solid organ transplantation (SOT) has increased the survival and quality of life for patients with end-stage organ failure by providing a potentially long-term treatment option. Although the availability of organs for transplantation has increased throughout the years, the demand greatly outweighs the supply. One possible solution for this problem is to extend the potential donor pool by using extended criteria donors. However, organs from such donors are more prone to ischemia reperfusion injury (IRI) resulting in higher rates of delayed graft function, acute and chronic graft rejection and worse overall SOT outcomes. This can be overcome by further investigating donor preconditioning strategies, graft perfusion and storage and by finding novel therapeutic agents that could reduce IRI. relaxin (RLX) is a peptide hormone with antifibrotic, antioxidant, anti-inflammatory and cytoprotective properties. The main research until now focused on heart failure; however, several preclinical studies showed its potentials for reducing IRI in SOT. The aim of this comprehensive review is to overview currently available literature on the possible role of RLX in reducing IRI and its positive impact on SOT.
['Jakubauskiene|Lina|L|', 'Jakubauskas|Matas|M|', 'Leber|Bettina|B|', 'Strupas|Kestutis|K|', 'Stiegler|Philipp|P|', 'Schemmer|Peter|P|']
D000818:Animals D051799:Delayed Graft Function D006801:Humans D016377:Organ Transplantation D011788:Quality of Life D012065:Relaxin D015427:Reperfusion Injury D014019:Tissue Donors
relaxin review heart transplantation kidney transplantation liver transplantation lung transplantation serelaxin